Seoul national unversity hospital
Seoul, South Korea
NCT Number: NCT07640867
This study is being conducted to evaluate the safety, tolerability, and pharmacokinetics of RCI001 eye drops 0.25% in healthy adult male participants. Pharmacokinetics means how the study drug is absorbed, distributed, and eliminated from the body over time.
Participants who meet the study requirements will be randomly assigned to receive either RCI001 eye drops 0.25% or placebo eye drops. The study treatment will be administered to the left eye according to the assigned dosing schedule. The study includes single-dose administration schedules and multiple-dose administration schedules for up to 15 days.
The study will monitor safety and tolerability through adverse event assessments, vital signs, physical examinations, electrocardiograms, laboratory tests, eye symptom assessments, and ophthalmic examinations. Blood samples will be collected at scheduled time points to measure the concentration of RCI001 in the blood.
Approximately 40 healthy adult male participants are planned to take part in this study.
Looking for future studies?
Notify Me19 year–50 year
Male
Interventional
Phase 1
Seoul, South Korea
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
RCI001 eye drops 0.25% administered to the left eye according to the assigned dosing schedule.
Other names: RCI001
Matching placebo eye drops administered to the left eye according to the assigned dosing schedule.
Other names: Matching placebo
Time frame: From informed consent through the post-study visit, up to Day 18 for single-administration cohorts and up to Day 32 for multiple-administration cohorts
The number and percentage of participants with adverse events will be summarized by treatment group. Adverse events will be assessed for seriousness, severity, relationship to the study drug, action taken, outcome, and whether they are treatment-emergent adverse events.
Time frame: From baseline through the post-study visit, up to Day 18 for single-administration cohorts and up to Day 32 for multiple-administration cohorts
Safety assessments will include vital signs, physical examinations, 12-lead electrocardiograms, clinical laboratory tests, ocular symptom assessments, and ophthalmic examinations. Clinically significant abnormalities will be summarized by treatment group.
Time frame: Predose on Day -1 through Day 11
Tmax will be calculated from plasma RCI001 concentration-time data after single administration.
Time frame: Predose on Day -1 through Day 25
Cmax will be calculated from plasma RCI001 concentration-time data after single administration.
Time frame: Predose on Day -1 through Day 11.
AUClast will be calculated from plasma RCI001 concentration-time data after single administration.
Time frame: Predose on Day -1 through Day 11.
AUCinf will be calculated from plasma RCI001 concentration-time data after single administration.
Time frame: Predose on Day -1 through Day 11.
Terminal elimination half-life will be calculated from plasma RCI001 concentration-time data after single administration.
Time frame: Predose on Day -1 through Day 11.
CL/F will be calculated from plasma RCI001 concentration-time data after single administration.
Time frame: Predose on Day -1 through Day 11.
Vz/F will be calculated from plasma RCI001 concentration-time data after single administration.
Time frame: Predose on Day -1 through Day 25.
Tmax,ss will be calculated from plasma RCI001 concentration-time data after multiple administration.
Time frame: Predose on Day -1 through Day 25.
Cmax,ss will be calculated from plasma RCI001 concentration-time data after multiple administration.
Time frame: Predose on Day -1 through Day 25.
Cmin,ss will be calculated from plasma RCI001 concentration-time data after multiple administration.
Time frame: Predose on Day -1 through Day 25.
Cavg,ss will be calculated from plasma RCI001 concentration-time data after multiple administration.
Time frame: Predose on Day -1 through Day 25.
Ctrough will be calculated from plasma RCI001 concentration-time data after multiple administration.
Time frame: Predose on Day -1 through Day 25.
AUCtau,ss will be calculated from plasma RCI001 concentration-time data after multiple administration.
Time frame: Predose on Day -1 through Day 25.
Terminal elimination half-life at steady state will be calculated from plasma RCI001 concentration-time data after multiple administration.
Time frame: Predose on Day -1 through Day 25.
CLss/F will be calculated from plasma RCI001 concentration-time data after multiple administration.
Time frame: Predose on Day -1 through Day 25.
Vz,ss/F will be calculated from plasma RCI001 concentration-time data after multiple administration.
Time frame: Predose on Day -1 through Day 25.
PTF will be calculated from plasma RCI001 concentration-time data after multiple administration.
Looking for future studies?
Notify MeRudacure
Industry
A Randomized, Double-Blind, Placebo-Controlled, Single- and Multiple-Administration Phase 1 Clinical Trial to Investigate the Pharmacokinetics, Safety, and Tolerability of RCI001 Eye Drops 0.25% in Healthy Male Subjects
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07298811
Dry Eye, Dry Eye Syndromes
Nanchang, Jiangxi, China
View Trial DetailsNCT04413370
Dry Eye, Dry Eye Syndromes
Guangzhou, Guangdong, China
View Trial DetailsNCT07175909
Dry Eye, Dry Eye Disease (DED)
Hong Kong
View Trial DetailsNCT07816419
Arthralgia, Asthenopia
Riyadh, Saudi Arabia
View Trial Details